<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03347422</url>
  </required_header>
  <id_info>
    <org_study_id>EFC16216</org_study_id>
    <secondary_id>2017-003539-12</secondary_id>
    <secondary_id>BIVV009-04</secondary_id>
    <nct_id>NCT03347422</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion</brief_title>
  <acronym>Cadenza</acronym>
  <official_title>A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioverativ, a Sanofi company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of Part A is to determine whether sutimlimab administration results in a greater&#xD;
      than or equal to (&gt;=)1.5 gram per deciliter (g/dL) increase in hemoglobin (Hgb) level and&#xD;
      avoidance of transfusion in participants with primary cold agglutinin disease (CAD) without a&#xD;
      recent history of blood transfusion. The purpose of Part B is to evaluate the long-term&#xD;
      safety and tolerability of sutimlimab in participants with primary CAD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The planned total study duration per patient is approximately 1.5 to 2.5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 17, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Percentage of Participants With Response (R)</measure>
    <time_frame>Up to Week 26</time_frame>
    <description>A participant will be considered a responder if he or she did not receive a blood transfusion from Week 5 through Week 26 (EOT) and did not receive treatment for primary cold agglutinin disease (CAD) beyond what is permitted per protocol. Additionally, the participant's hemoglobin (Hgb) level must meet the following criterion: Hgb increase greater than or equal to (&gt;=) 1.5 gram per deciliter (g/dL) from baseline (defined as the last Hgb value before administration of the first dose of study drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs)</measure>
    <time_frame>Approximately 1 year from end of Week 26 of Part A</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: Mean Change From Baseline in Hemoglobin (Hgb) Level up to Week 26</measure>
    <time_frame>Baseline Up to Week 26</time_frame>
    <description>Mean change from baseline in hemoglobin (Hgb) level up to Week 26 will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Mean Change From Baseline in Bilirubin up to Week 26</measure>
    <time_frame>Baseline up to Week 26</time_frame>
    <description>Mean change from baseline in bilirubin up to Week 26 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale Score (Quality of Life)</measure>
    <time_frame>Baseline Up to Week 26</time_frame>
    <description>FACIT-Fatigue scale consists of 13 questions assessed using a 5 point scale (0=not at all; 1 = a little bit, 2 = somewhat, 3 = quite a bit and 4 = very much). Responses to each question are added to obtain a total score. The range of possible scores is 0-52, with higher score indicating more fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Mean Change From Baseline in Lactate Dehydrogenase (LDH) up to Week 26</measure>
    <time_frame>Baseline up to Week 26</time_frame>
    <description>Mean change from baseline in LDH up to Week 26 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Percentage of Participants With Solicited Symptomatic Anemia at End of Treatment (EOT)</measure>
    <time_frame>At Part A EOT (Day 182)</time_frame>
    <description>Symptomatic anemia is defined as fatigue, weakness, shortness of breath, palpitations, fast heart beat, light headedness, and/or chest pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Mean Change From Week 27 in Hemoglobin (Hgb) Level</measure>
    <time_frame>From Week 27 (Part B baseline) up to Week 77</time_frame>
    <description>Mean change from week 27 (Part B baseline) in Hemoglobin (Hgb) level up to Week 77 will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Mean Change From Week 27 in Bilirubin (total)</measure>
    <time_frame>From Week 27 (Part B baseline) up to Week 77</time_frame>
    <description>Mean change from week 27 (Part B baseline) in Bilirubin (total) level up to Week 77 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Mean Change From Week 27 in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale Score (Quality of Life)</measure>
    <time_frame>From Week 27 (Part B baseline) up to Week 77</time_frame>
    <description>FACIT-Fatigue scale consists of 13 questions assessed using a 5 point scale (0=not at all; 1 = a little bit, 2 = somewhat, 3 = quite a bit and 4 = very much). Responses to each question are added to obtain a total score. The range of possible scores is 0-52, with higher score indicating more fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Mean Change From Week 27 in five level EuroQol five dimensions questionnaire (EQ-5D-5L)</measure>
    <time_frame>From Week 27 (Part B baseline) up to Week 77</time_frame>
    <description>The EQ-5D descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has a 5-level response: no problems, slight problems, moderate problems, severe problems, and extreme problems. A scale with score 0-100 is used to collect response on current health status. Higher the score better the health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Mean Change From Week 27 in 12-item short form survey (SF-12)</measure>
    <time_frame>From Week 27 (Part B baseline) up to Week 77</time_frame>
    <description>SF-12 health survey is a self-reported questionnaire to measure participant's profile of functional health and well-being. It includes 12 questions (Q).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Patient's Global Impression of [Fatigue] Severity (PGIS) total score in different timepoints</measure>
    <time_frame>From Week 27 (Part B baseline) up to Week 77</time_frame>
    <description>PGIS is a 5-point response to the severity of the fatigue over the past weeks where 1 indicates No fatigue&quot; to 5 as &quot;very severe&quot;. The assessments will be performed every 3 months beginning after Week 27 up to Week 77.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Patient's Global Impression of Change (PGIC) total score in different timepoints</measure>
    <time_frame>From Week 27 (Part B baseline) up to Week 77</time_frame>
    <description>PGIC is a 7-point response to the change of overall status of quality of life where 1 indicates &quot;Very much improved&quot; to 7 as &quot;very much worse&quot;. The assessments will be performed every 3 months beginning after Week 27 up to Week 77.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Mean Change From Week 27 in Lactate Dehydrogenase (LDH) level</measure>
    <time_frame>From Week 27 (Part B baseline) up to Week 77</time_frame>
    <description>Mean change from week 27 (Part B baseline) in LDH level up to Week 77 will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of transfusions</measure>
    <time_frame>From Week 27 (Part B baseline) up to Week 77</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Mean Change From Week 27 in Haptoglobin</measure>
    <time_frame>From Week 27 (Part B baseline) up to Week 77</time_frame>
    <description>Mean change from Week 27 (Part B baseline) in Haptoglobin up to Week 77 will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of healthcare visits by type</measure>
    <time_frame>Approximately 1 year from end of Week 26 of Part A</time_frame>
    <description>Number of healthcare visits by type such as office visit, hospital ER visit, hospitalization, and ICU stay will be reported for the approximately 1 year duration of Part B</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cold Agglutinin Disease</condition>
  <arm_group>
    <arm_group_label>Part A: sutimlimab or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part A, participants will be randomized 1:1 to receive an intravenous (IV) infusion of sutimlimab or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Response Extension Phase (sutimlimab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part B, all participants will undergo blinded cross-over loading doses to allow all participants to receive sutimlimab while maintaining Part A blinding.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sutimlimab (BIVV009)</intervention_name>
    <description>Pharmaceutical form:solution for injection Route of administration: intravenous(i.v.)</description>
    <arm_group_label>Part A: sutimlimab or Placebo</arm_group_label>
    <arm_group_label>Part B: Response Extension Phase (sutimlimab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Pharmaceutical form:solution for injection Route of administration: intravenous(i.v.)</description>
    <arm_group_label>Part A: sutimlimab or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  Body weight of greater than or equal to (&gt;=) 39 kilogram (kg) at Screening&#xD;
&#xD;
          -  Confirmed diagnosis of primary cold agglutinin disease (CAD) based on the following&#xD;
             criteria: a) Chronic hemolysis, b) Polyspecific direct antiglobulin test (DAT)&#xD;
             positive, c) Monospecific DAT strongly positive for C3d, d) Cold agglutinin titer &gt;=&#xD;
             64 at 4 degree Celsius, and e) Immunoglobulin G (IgG) DAT less than or equal to (&lt;=)&#xD;
             1+, and, f) No overt malignant disease&#xD;
&#xD;
          -  Hemoglobin level &lt;= 10.0 gram per deciliter (g/dL)&#xD;
&#xD;
          -  Bilirubin level above the normal reference range, including patients with Gilbert's&#xD;
             Syndrome&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Cold agglutinin syndrome secondary to infection, rheumatologic disease, or active&#xD;
             hematologic malignancy&#xD;
&#xD;
          -  Clinically relevant infection of any kind within the month preceding enrollment&#xD;
             (example, active hepatitis C, pneumonia)&#xD;
&#xD;
          -  Clinical diagnosis of systemic lupus erythematosus (SLE); or other autoimmune&#xD;
             disorders with anti-nuclear antibodies at Screening. Anti-nuclear antibodies of&#xD;
             long-standing duration without associated clinical symptoms will be adjudicated on a&#xD;
             case-by-case basis during the Confirmatory Review of Patient Eligibility&#xD;
&#xD;
          -  Positive hepatitis panel (including hepatitis B surface antigen and/or hepatitis C&#xD;
             virus antibody) prior to or at Screening&#xD;
&#xD;
          -  Positive human immunodeficiency virus (HIV) antibody at Screening&#xD;
&#xD;
          -  Treatment with rituximab monotherapy within 3 months or rituximab combination&#xD;
             therapies (example, with bendamustine, fludarabine, ibrutinib, or cytotoxic drugs)&#xD;
             within 6 months prior to enrollment&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Oncology Associates PC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC/Keck School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Georgetown</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College at Westchester Medical Center</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UW Hospitals and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC Health Clinics</name>
      <address>
        <city>Buderim</city>
        <state>Queensland</state>
        <zip>4556</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ballarat Oncology &amp; Haematology</name>
      <address>
        <city>Ballarat</city>
        <state>Victoria</state>
        <zip>3350</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perth Blood Institute</name>
      <address>
        <city>West Perth</city>
        <state>Western Australia</state>
        <zip>6005</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZNA Stuivenberg</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers Cedex 9</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Hämatologie-Onkologie</name>
      <address>
        <city>Dresden</city>
        <zip>1307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Ulm, Inst Klin. Transfusions. Immungen</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laniado Hospital</name>
      <address>
        <city>Netanya</city>
        <zip>4244916</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A. O. Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCSS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia- Policlinico &quot;A. Gemelli&quot;</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia Ospedale San Bortolo</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Society Himeji Hospital</name>
      <address>
        <city>Himeji</city>
        <state>Hyogo</state>
        <zip>670-8540</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ishikawa Prefectural Central Hospital</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa-ken</state>
        <zip>9208530</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokai University Hospital</name>
      <address>
        <city>Isehara</city>
        <state>Kanagawa</state>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Medical University Hospital</name>
      <address>
        <city>Iruma-gun</city>
        <state>Saitama-Ken</state>
        <zip>350-0495</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aichi Medical University Hospital</name>
      <address>
        <city>Nagakute</city>
        <zip>480-1195</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5053</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Olavs Hospital, Avdeling for blodsykdommer</name>
      <address>
        <city>Trondheim</city>
        <zip>7030</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinci i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Peset</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St James Hospital, Leeds</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust, Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London</name>
      <address>
        <city>London</city>
        <zip>WC1E 6AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>November 16, 2017</study_first_submitted>
  <study_first_submitted_qc>November 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2017</study_first_posted>
  <last_update_submitted>September 1, 2020</last_update_submitted>
  <last_update_submitted_qc>September 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

